甲状腺转录因子-1在滤泡源性甲状腺肿瘤中的表达及其与RET等3种基因表达的相关性研究

Expression of TTF-1 in thyroid tumors originating from follicular epithelium and its correlation with expression of RET, Galectin-3 and Mucin-1 genes

目的 探讨甲状腺转录因子 (TTF 1)在甲状腺肿瘤及滤泡上皮细胞不同部位的表达及与RET、Galectin 3(Gal 3)和粘蛋白 1(MUC1)基因产物的相关性。方法 应用免疫组织化学 (SP)法 ,对 133例甲状腺手术切除标本进行了TTF 1、RET、Gal 3和MUC1的联合检测。结果 (1)TTF 1:在病变 (瘤 )细胞核、质及周围正常组织的细胞核均有表达 ,4种不同病理类型的周围正常滤泡 ,良、恶性病变的胞核阳性表达差别无显著意义 (P >0 0 5 )。而胞质型TTF 1在良性病变的表达率为 2 7 4 % ,恶性肿瘤的表达率为 6 6 1% ,良性病变与两种甲状腺癌组织的差异有显著意义 (P <0 0 5 ) ,恶性肿瘤高于良性病变。(2 )RET :腺瘤组织阳性表达率为 38 9% ,乳头状癌、滤泡性癌阳性表达率分别为 88 4 %和87 5 % ,腺瘤与乳头状癌、滤泡性癌的差异有显著意义 (P <0 0 5 )。 (3)Gal 3、MUC1:良性病变阳性率分别为 38 4 %和 2 3 3% ,恶性肿瘤的阳性率分别为 88 1%和 5 0 9% ,良性病变 (结节性甲状腺肿和腺瘤 )阳性率低于甲状腺乳头状癌和滤泡性癌 (P <0 0 5 ) ;甲状腺癌中Gal 3和MUC1表达基本平行 ,但Gal 3的敏感性高于MUC1;部分腺瘤中可见灶性Gal 3和MUC1同时阳性。而胞质型TTF 1表达与Gal 3、MUC1阳性表达有关。结论 TTF

Objective To explore the expression of thyroid transcription factor 1 (TTF 1) in thyroid tumors and in different parts of follicular epithelium and the correlation of expression of TTF 1 with the expression of RET, galectin 3(Gal 3) and mucin 1 (MUC1) genes. Methods One hundred thirty three samples of resected thyroid tumors were examined by streptavidin/peroxidase (S P) immunohistochemical technique to detectthe expression of TTF 1 and RET, Gal 3, and MUC1 genes. Results (1) TTF 1 was expressed in the nuclei and cytoplasm of different kinds of tumor cells and normal cells around the tumors. There was no significant difference between the expression of TTF 1 in nuclei of malignant thyroid tumor cells and that in nuclei of benign thyroid tumor cells ( P >0 05) The positive expression rate of TTF 1 was 27 40% in cytoplasm of benign tumor and was 66 10% in cytoplasm of malignant tumor was 66 10% ( P <0 05) (2) The expression rate of RET gene was 38 9% in thyroid adenoma, 88 4% in papillary carcinoma, and 87 5% in follicular carcinoma The difference of expression rate of RET gene between adenoma and both of papillary and follicular carcinomas was statistically significant( P <0 05) (3) The expression rate of MUC1 was 23 3% in benign tumor and 50 9% in malignant tumor The expression rate of MUC1 was lower in benign thyroid diseases (nodular goiter and adenoma) than in thyroid papilary carcinoma and follicular carcidema ( P <0 05) (4) The expression rate of Gal 3 gene was 38 4% in benign tumor and 88 1% in malignant tumor (5) The expression rates of Gal 3 and MUC1 in benign lesions (nodular goiter and adenoma) were lower than those in thyroid papillary and follicular carcinomas( P <0 05) The expression of Gal 3 and that of MUC1 in thyroid carcinomas were fundamentally parallel However, the sensitivity of Gal 3 was higher than that of MUC1 In part of adenomas Gal 1 and MUC1 were positive locally simultaneously The expression of TTF 1 in cytoplasm was associated with that of Gal 3 and MUC1 Conclusion The expression of TTF 1 in nucleus is a phenomenon common to both normal and pathological thyroid follicles Combined tests of RET, Gal 3 and MUC1 may act as the diagnostic markers to distinguish benign follicular tumor from malignant ones Expression of TTF 1 in cytoplasm is probably a characteristic of malignant phenotypes of thyroid tumors